Class IIReported 2024-12-18

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20

Recalled by Mylan Institutional, Inc.

Reason for Recall

Subpotent and Superpotent Drug

Recall Number

D-0133-2025

Classification

Class II

Status

Ongoing

Category

drug

Initiated

2024-11-19

Reported

2024-12-18

Distribution

Nationwide in the USA.

Code Info

Lot #: 3115893, Exp. Date 6/2025

Source: openFDA enforcement report. WhichRecall is not affiliated with the FDA. See our disclaimer.